Terms: = Lung cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
5661 results:
1. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
Yin X; Liu X; Ren F; Meng X
Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
[TBL] [Abstract] [Full Text] [Related]
2. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
[TBL] [Abstract] [Full Text] [Related]
3. Implications of GCLC in prognosis and immunity of lung adenocarcinoma and multi-omics regulation mechanisms.
Huang Z; Liang F; Wu J; Huang Z; Li Y; Huang X; Liu Z
BMC Pulm Med; 2024 May; 24(1):239. PubMed ID: 38750474
[TBL] [Abstract] [Full Text] [Related]
4. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathological characteristics and tumor infiltrating immune cells associations of pd-l1 tumor expression in non-small cell lung cancer patients.
Aazzane O; Bakhtaoui FZ; Stitou S; Fellah H; Karkouri M
Tunis Med; 2024 Apr; 102(4):223-228. PubMed ID: 38746962
[TBL] [Abstract] [Full Text] [Related]
6. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/pd-l1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.
Sui P; Liu X; Zhong C; Sha Z
Sci Rep; 2024 May; 14(1):10873. PubMed ID: 38740918
[TBL] [Abstract] [Full Text] [Related]
7. A rare case of TFEB/6p21/VEGFA-amplified renal cell carcinoma diagnosed by whole-exome sequencing: clinicopathological and genetic feature report and literature review.
Zhang R; Ding M; Zhu X; Li X; Hu Q; Tao L; Hu W; Zou H
Diagn Pathol; 2024 May; 19(1):66. PubMed ID: 38730456
[TBL] [Abstract] [Full Text] [Related]
8. Exploring the efficacy and molecular mechanism of Danhong injection comprehensively in the treatment of idiopathic pulmonary fibrosis by combining meta-analysis, network pharmacology, and molecular docking methods.
Wu X; Li W; Luo Z; Chen Y
Medicine (Baltimore); 2024 May; 103(19):e38133. PubMed ID: 38728523
[TBL] [Abstract] [Full Text] [Related]
9. Clinical Validation of Artificial Intelligence-Powered pd-l1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell lung cancer.
Kim H; Kim S; Choi S; Park C; Park S; Pereira S; Ma M; Yoo D; Paeng K; Jung W; Park S; Ock CY; Lee SH; Choi YL; Chung JH
JCO Precis Oncol; 2024 May; 8():e2300556. PubMed ID: 38723233
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy and safety of PD-1/pd-l1 inhibitors in elderly patients with advanced non-small cell lung cancer.
Li L; Xu C; Wang W; Zhang Q
Clin Respir J; 2024 May; 18(5):e13763. PubMed ID: 38717297
[TBL] [Abstract] [Full Text] [Related]
11. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer.
Wang M; Jing X; Chen F; Lu S; Sun Y
BMC Cancer; 2024 May; 24(1):569. PubMed ID: 38714983
[TBL] [Abstract] [Full Text] [Related]
12.
Krencz I; Sztankovics D; Sebestyén A; Pápay J; Dankó T; Moldvai D; Lutz E; Khoor A
Pathol Oncol Res; 2024; 30():1611593. PubMed ID: 38706776
[No Abstract] [Full Text] [Related]
13. The role of chemoradiotherapy and immunotherapy in stage III NSCLC.
Orosz Z; Kovács Á
Pathol Oncol Res; 2024; 30():1611716. PubMed ID: 38706775
[TBL] [Abstract] [Full Text] [Related]
14. Patient-derived tumoroids and proteomic signatures: tools for early drug discovery.
Lê H; Deforges J; Cutolo P; Lamarque A; Hua G; Lindner V; Jain S; Balloul JM; Benkirane-Jessel N; Quéméneur E
Front Immunol; 2024; 15():1379613. PubMed ID: 38698850
[TBL] [Abstract] [Full Text] [Related]
15. Genetically Edited Cascade Nanozymes for cancer Immunotherapy.
Zhang J; Pan Y; Liu L; Xu Y; Zhao C; Liu W; Rao L
ACS Nano; 2024 May; 18(19):12295-12310. PubMed ID: 38695532
[TBL] [Abstract] [Full Text] [Related]
16. Applications of Artificial Intelligence in lung Pathology.
Hartman DJ
Surg Pathol Clin; 2024 Jun; 17(2):321-328. PubMed ID: 38692814
[TBL] [Abstract] [Full Text] [Related]
17. Microsatellite Instability, Mismatch Repair, and Tumor Mutation Burden in lung cancer.
Rosca OC; Vele OE
Surg Pathol Clin; 2024 Jun; 17(2):295-305. PubMed ID: 38692812
[TBL] [Abstract] [Full Text] [Related]
18. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
Kong Y; Hong L; Xu XC; Chen YF; Xu J
PLoS One; 2024; 19(4):e0301931. PubMed ID: 38683829
[TBL] [Abstract] [Full Text] [Related]
19. FOXA1/UBE2T Inhibits CD8
Pu J; Zhang D; Wang B; Zhu P; Yang W; Wang K; Yang Z; Song Q
Front Biosci (Landmark Ed); 2024 Apr; 29(4):134. PubMed ID: 38682180
[TBL] [Abstract] [Full Text] [Related]
20. Molecular Diagnostics and Treatment Patterns in Metastatic Non-small Cell lung cancer Patients: Real World Evidence from Greece: LACHESIS Study.
Charpidou A; Mani M; Kokkotou E; Stournara L; Stathelou L; Antoniadou K; Argyropoulos E; Syrigos KN
Anticancer Res; 2024 May; 44(5):2063-2072. PubMed ID: 38677737
[TBL] [Abstract] [Full Text] [Related]
[Next]